^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Marginal Zone Lymphoma |
| Drug: | Zydelig (idelalisib) (PI3Kδ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Marginal Zone Lymphoma: Second-line and Subsequent Therapy...Other recommended regimens…PI3K inhibitors (relapsed/refractory after 2 prior therapies)…Idelalisib
